Sanovel

What Sanovel does

Sanovel İlaç Sanayi ve Ticaret Anonim Şirketi is a privately held Turkish pharmaceutical manufacturer that develops, produces, and distributes generic and innovative prescription medications across cardiovascular, endocrine/metabolism, neurology, psychiatry, infectious disease, hepatology, hematology, multiple sclerosis, respiratory, and pain/inflammation therapeutic areas. Its branded portfolio includes more than 20 named products such as Amlokard (amlodipine), Ator (atorvastatin), Calira (dapagliflozin), Cardofix (valsartan-amlodipine), Cardopan (valsartan), Cedrina (quetiapine), Hepagard (entecavir), and Avoran (teriflunomide), spanning tablets, capsules, ODT formulations, oral suspensions, and injectables. The company operates a single-site modern production campus in Silivri, Istanbul, established in 2006 across 125,000 square meters (59,000 sqm indoor), with capacity for 300 million boxes annually across solid, liquid, semi-solid, and sterile dosage forms, plus a dedicated biotechnology production facility and an on-site R&D center.

Core technology stack centers on cGMP-compliant manufacturing with a Quality by Design (QbD) approach and the first deployed SDMS-VP laboratory data management system in Turkey, enabling electronic records management under 21 CFR Part 11 and Eudralex Annex-11. R&D capabilities span formulation optimization, chemical analysis, process optimization, technology transfer, CMC, and innovative dosage form development (bi/tri-layer tablets, capsules-in-capsule, pellet-based, ODT, and combination formulations). The company holds ISO 14001, ISO 45001, and ISO 50001 certifications, and operates a solar energy system for manufacturing operations.

Sanovel runs a sales-led B2B go-to-market targeting healthcare professionals (physicians, pharmacists, hospitals, and medical institutions), with the products section of its website restricted to licensed prescribers. Distribution flows through Turkish pharmacy networks for outpatient prescriptions and direct field-sales engagement for institutional buyers; products are also positioned for registration in the EU, US, and Canada. The company maintains two adjacent operating subsidiaries (Aset İlaç and Adilna İlaç) for shared pharmacovigilance and data protection purposes. No funding rounds, parent company, or external private equity ownership are disclosed. AI deployment is limited to internal operations, including the AI-powered Sanovel Campus learning platform and HR process automation, with no disclosed AI applications in core pharmaceutical R&D.

Name

Sanovel

Legal name

Sanovel İlaç Sanayi ve Ticaret Anonim Şirketi

Website

https://sanovel.com.tr

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Sanovel is a privately held Turkish pharmaceutical manufacturer producing generic and innovative prescription drugs across 10+ therapeutic areas (cardiovascular, diabetes, neurology, psychiatry, infectious disease, hepatology, MS, respiratory, pain) at a 300-million-box-capacity Silivri facility, sold to physicians, pharmacists, and medical institutions.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Generic pharmaceuticals
• Prescription medications
• Pharmaceutical manufacturing
• Cardiovascular medications
• Sterile injectables production

Headquarters

HQ city

Sariyer

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Sanovel generates revenue through the manufacture and sale of generic pharmaceutical products. Products span multiple therapeutic areas including cardiovascular, endocrine/metabolism, neurology, psychiatry, infectious diseases, hepatology, hematology, multiple sclerosis, respiratory, and pain/inflammation. Products are sold through pharmacies and medical institutions in Turkey and internationally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sanovel develops, manufactures, and sells a broad portfolio of generic prescription pharmaceutical products across multiple therapeutic areas, including cardiovascular, endocrine/metabolism, neurology, psychiatry, infectious diseases, hepatology, hematology, multiple sclerosis, respiratory, and pain/inflammation. Products are produced at cGMP-compliant facilities in Silivri, Istanbul under the Sanovel İlaç Sanayi ve Ticaret Anonim Şirketi legal entity and are sold under multiple brand names such as Amlokard, Ator, Avoran, Calira, Cardofix, Cardopan, Cedrina, Cempes, Colnar, Cyovel, Diyatix, Doenza, Dropia, Eklips, Exen, Fesor, Flupamid, Hepagard, and İgnis.

Product overview

Sanovel is a Turkish pharmaceutical company offering a diverse portfolio of prescription medications across multiple therapeutic areas including cardiovascular, endocrine/metabolism, neurology, psychiatry, infectious diseases, hepatology, hematology, pain/inflammation, and multiple sclerosis. The portfolio includes branded products such as Amlokard (amlodipine), Ator (atorvastatin), Calira (dapagliflozin), Cardofix (valsartan-amlodipine combination), Cardopan (valsartan), Cedrina (quetiapine), Doenza (donepezil), and others. The company also operates Sanovel Campus, an internal AI-powered digital learning platform for employee development. Sanovel maintains manufacturing facilities in Silivri, Istanbul with cGMP-compliant production capabilities across solid, liquid, semi-solid, and sterile pharmaceutical forms.

Differentiator

Problem solved

Functional benefit

Products and services

• Amlokard Calcium channel blocker (amlodipine) for cardiovascular treatment, available in 5mg and 10mg dosages.
• Ator Statin medication (atorvastatin) for cardiovascular health, available in 10mg, 20mg, 40mg, and 80mg dosages.
• Avoran Teriflunomide 14mg for multiple sclerosis treatment.
• Calira Dapagliflozin SGLT2 inhibitor for Type 2 diabetes treatment, available as standalone 10mg and in combination formulations (Calira-Met, Calira-Met XR) with metformin.
• Cardofix Combination valsartan-amlodipine product for hypertension, available in multiple dosage strengths including fixed-dose triple combinations with HCTZ.
• Cardopan Valsartan angiotensin receptor blocker for hypertension, available in 80mg, 160mg, and 320mg dosages with combination product Cardopan Plus.
• Cedrina Quetiapine fumarate atypical antipsychotic available in 25mg, 50mg, 100mg, 200mg, 300mg, and 400mg dosages.
• Cempes Broad-spectrum antibiotic (cefdinir) available in pediatric oral suspension (125mg/5ml, 250mg/5ml) and capsule (300mg, 600mg) formulations.
• Colnar Rosuvastatin statin for cholesterol management, available in 5mg, 10mg, 20mg, and 40mg dosages.
• Cyovel Oseltamivir 75mg neuraminidase inhibitor antiviral for influenza treatment.
• Diyatix Vildagliptin DPP-4 inhibitor for Type 2 diabetes, available as standalone 50mg and combination Diyatix Plus with metformin (850mg, 1000mg).
• Doenza Donepezil HCl acetylcholinesterase inhibitor for Alzheimer's disease, available in 5mg and 10mg tablets and ODT (orally disintegrating tablet) formulations.
• Dropia Pioglitazone thiazolidinedione for Type 2 diabetes, available in 15mg, 30mg, and 45mg dosages with combination Dropia-Met formulations.
• Efikas MR Modified-release gliclazide for Type 2 diabetes, available in 30mg and 60mg strengths.
• Eklips Losartan potassium angiotensin receptor blocker for hypertension available in 50mg and 100mg dosages, with combination products Eklips Plus and Eklips Fort.
• Exen Meloxicam NSAID for pain and inflammation, available in tablet and injectable formulations.
• Fesor Deferasirox iron chelator for chronic iron overload, available in 250mg and 500mg dosages.
• Hepagard Entecavir nucleoside analogue antiviral for hepatitis B, available in 0.5mg and 1mg dosages.
• Ayra Candesartan-based angiotensin receptor blocker for hypertension, available in 8mg and 16mg dosages with combination formulation Ayra Plus.
• İgnis Aripiprazole monohydrate atypical antipsychotic available in oral solution formulation (1mg/ml).
• Flupamid Indapamide diuretic for hypertension, available in 1.5mg and 2.5mg dosages.
• Camilla Ticagrelor 90mg antiplatelet agent for cardiovascular conditions.

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Türkiye İlaç ve Tıbbi Cihaz Kurumu (Turkish Medicines and Medical Devices Agency)coreOthersRegulatory partnership for drug safety monitoring. Sanovel reports adverse drug reactions and pharmacovigilance data to the Turkish Medicines and Medical Devices Agency in compliance with national pharmaceutical regulations.
• World Health Organization (WHO)minorOthersData sharing partnership within the Drug Monitoring and Cooperation Programme. Adverse event data is anonymized and entered into the WHO database for international pharmacovigilance coordination.
• PR Agency (for event organization)minorImplementation/ SI/ Consulting PartnerWorking with PR agency for organizing corporate events such as the 'Cumhuriyet'in 102. Yılında 102 Kız Öğrencimize Koçluk Desteği' project announcement and media communications.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive cardiovascular, CNS, and metabolic portfolios. Provides a global benchmark for Sanovel's generic-pharma business model and international expansion pathway.
• Hikma Pharmaceuticals: Multinational generic and specialty pharmaceutical manufacturer with strong MENA footprint and growing US injectable business. Comparable in generic-pharma operating model and emerging-markets focus; broader geographically than Sanovel.
• Viatris: Global generics and specialty manufacturer formed from Mylan and Upjohn, with broad cardiovascular, CNS, and metabolic portfolios. Comparable in generic-pharma focus and global commercial reach; broader in scale and product depth than Sanovel.

Direct peers

• Nobel İlaç: Turkish pharmaceutical manufacturer with branded generic products and own manufacturing facilities. Comparable to Sanovel in domestic focus, product portfolio breadth, and contract manufacturing orientation.
• Bilim İlaç: Turkish pharmaceutical producer with branded generics across multiple therapeutic categories including cardiovascular and CNS. Comparable to Sanovel in product diversification and domestic market positioning.
• Deva Holding: Turkish pharmaceutical manufacturer producing generics across multiple therapeutic categories with significant manufacturing capacity. Directly comparable to Sanovel in scale, product mix, and home-market emphasis.
• KRKA: Slovenia-based generic pharmaceutical manufacturer of similar scale to Sanovel, producing prescription generics across cardiovascular, CNS, and metabolic areas. Comparable in vertical integration, multi-therapy breadth, and focus on emerging European markets.
• Atabay İlaç: Turkish pharmaceutical manufacturer with branded generics and own production facilities, including active pharmaceutical ingredient capabilities. Comparable to Sanovel as a domestic Turkish pharma manufacturer with similar therapeutic breadth and regulated-market ambitions.
• Abdi İbrahim: Turkey's largest domestic pharmaceutical manufacturer with a broad branded-generic portfolio across cardiovascular, metabolic, and other therapeutic areas. Most directly comparable Turkish peer to Sanovel in product breadth, cGMP manufacturing, and domestic market focus.
• Eczacıbaşı İlaç: Turkish pharmaceutical company with branded generics in similar therapeutic areas to Sanovel, including cardiovascular and central nervous system. Comparable in domestic positioning and generic-pharma business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/SanovelFarma
• Facebookfacebook.com/sanovel
• LinkedInlinkedin.com/company/sanovelilac

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanovel